Navigation Links
Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies
Date:4/4/2011

NEW YORK, April 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pain Therapeutics - Drugs, Markets and Companies

http://www.reportlinker.com/p0203548/Pain-Therapeutics---Drugs-Markets-and-Companies.html

This report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis, neuropathic pain and cancer pain. Because pain is a subjective sensation, it is difficult to evaluate objectively in clinical trials. Various tools for pain measurement are described, including brain imaging.

Most of the currently used analgesic drugs fall into the categories of opioids and nonsteroidal anti-inflammatory drugs such as COX-2 inhibitors. Non-opioid analgesics include ketamine, a N-methyl-D-aspartate receptor antagonist. Adjuvant analgesics include antidepressants and antiepileptic drugs used for the treatment of neuropathic pain. Management of pain is multidisciplinary and includes both pharmacological and non-pharmacological methods such as acupuncture, transcutaneous electrical nerve stimulation and surgery. Various pain syndromes require different approaches in management, for example, the main category of drugs for migraine are triptans such as sumatriptan.

Drug delivery is an important consideration in pain treatment. Controlled release preparations provide a steady delivery of analgesics. Well-known non-injection methods such astransdermal, pulmonary and intranasal application have been used. Topical analgesics and local anesthetics are also available. Devices such as impla
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reportlinker Adds Molecular Diagnostics in Infectious Disease Testing
2. Reportlinker Adds Top 500 Pharmaceuticals Industry Report (Global)
3. Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
4. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
5. Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region
6. Reportlinker Adds Medical Imaging Markets
7. Reportlinker Adds Cardiac Marker Diagnostic Testing Markets
8. Reportlinker Adds Point of Care Diagnostic Testing World Markets
9. Reportlinker Adds Endoscopy Devices Market to 2016 - Need For Therapeutic Endoscopy and Advancements in HD Endoscopy to Drive Flexible Endoscopes
10. Reportlinker Adds Top 150 Antibiotic Manufacturers (Global)
11. Reportlinker Adds Orthopedics Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 2014 The Cadence Fitness & Health Center has ... Medical Fitness Association, a non-profit organization assisting medically integrated ... The Cadence Fitness & Health Center is the only ... in the Chicagoland area. "The certification means ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Boston Scientific Corporation (NYSE: BSX ) ... quality of life outcomes, based on one-year data from ... while the overall cost effectiveness of percutaneous coronary intervention ... according to patient characteristics, PCI was more cost effective ...
... to be presented at Israel Society of ... reach 5 months from single treatment - Data ... scores of expensive injections MISGAV, Israel and LONDON, March ... that the latest, encouraging results of the Company,s ongoing ...
Cached Medicine Technology:SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 5Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 2Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 3Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 4
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research Institute ... annual Founders Dinner for their support of TGen,s research ... place March 28 in Scottsdale. , Catherine Ivy, Founder ... received TGen,s John S. McCain Leadership Award, named for ...
(Date:4/16/2014)... April 16, 2014 According to a new study, ... patients with one to two small polyps are consistent ... This may be an appropriate target for quality indicators. ... quantify adherence to guidelines for timing of repeat colonoscopy ...
(Date:4/15/2014)... frozen fish caused nearly half of all injuries aboard ... on freezer-longliner vessels operating off the coast of Alaska, ... of those injuries and others aboard the two types ... and the research methods used in the study could ...
(Date:4/15/2014)... the University of California, San Diego School of Medicine have ... C virus get liver disease and why the virus is ... , The hard-to-kill pathogen, which infects an estimated 200 million ... mitochondria dismantling the cell,s innate ability to fight infection. ...
Breaking Medicine News(10 mins):Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Changes in processing, handling could reduce commercial fishing injuries 2Health News:Breaking bad mitochondria 2
... Favorite, and ,Have Fun Helping It ... ... Recession? Killer bees? No! Only positive predictions, please.,That,s the attitude of Richard ... debut last month., *(PHOTO 72dpi: Send2Press.com/mediaboom/07-1115-DSamson_72dpi.jpg), *(Photo Caption: SuperLife founder ...
... /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. (OTC Bullion ... medicinal and diagnostic products in China,today announced that ... Company,s Form 10QSB for the fiscal quarters ended ... filed its full year 2006 amendments on,November 8, ...
... 18 Escalon Medical Corp.,(Nasdaq Capital Market: ESMC) ... clearance from the U.S. Food and Drug,Administration (FDA) ... differential Hematology Analyzer. Drew Scientific plans to,commence shipments ... month-end., "The FDA clearance represents a major ...
... PHILADELPHIA A new brain imaging study by researchers ... Pennsylvania shows that cigarette cravings in smokers who are ... specific regions of the brain. Using a novel method ... MD, associate professor of Neurology at Penn, this study ...
... (NYSE: CDI ),announced today that the Life ... been awarded a contract from CJ CheilJedang,Corporation to ... manufacturing complex to be located in Osong, Korea. ... center for global,distribution of oral solid and sterile ...
... where he worked as a ... ... Dikembe,Mutombo, who is known as much for his philanthropy as his storied ... organization prepare its entry into his home country, the,Democratic Republic of Congo ...
Cached Medicine News:Health News:Six Positive Predictions for 2008, from SuperLife World Service 2Health News:China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 2Health News:Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System 2Health News:Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System 3Health News:New neuroimaging study identifies 'brain signature' for cigarette cravings 2Health News:CDI-Life Sciences Selected by CJ CheilJedang Corp. to Provide Engineering Design for Major Pharmaceutical Complex in Korea 2Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 2Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 3Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 4